Mesa Laboratories, Inc. Form 10-K Summary
Reporting period: The supplied filing is Mesa Laboratories, Inc.’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, filed May 30, 2023. This does not match the request metadata identifying “2021 Q4.” Fiscal years 2023, 2022, and 2021 are presented for comparison.
Business context
Mesa manufactures and sells life sciences tools and critical quality-control products and services, primarily in regulated healthcare, pharmaceutical, medical device, and laboratory markets. Its four reportable segments are Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Approximately 46% of fiscal 2023 revenue was generated outside the United States.
The company completed the $300.8 million Agena Bioscience acquisition in October 2021 and acquired substantially all assets of Belyntic GmbH’s peptide-purification business in November 2022 for $4.95 million, with up to $1.5 million of additional contingent consideration.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $219.1 million | $184.3 million | 19% |
| Gross profit | $133.7 million | $109.1 million | 23% |
| Gross margin | 61.0% | 59.2% | Up approximately 2 percentage points |
| Operating income | $3.3 million | $4.7 million | Down 29% |
| Net income | $0.9 million | $1.9 million | Down 50% |
| Basic and diluted EPS | $0.17 | $0.36 basic; $0.35 diluted | Down |
| Cash flow from operations | $28.0 million | $39.2 million | Down $11.2 million |
Revenue growth was primarily acquisition-related; organic revenue growth was 0.6%. Product revenue was $180.5 million and service revenue was $38.6 million. Adjusted operating income, excluding acquired-intangible amortization, stock-based compensation, and impairment charges, was $44.7 million versus $37.9 million in fiscal 2022.
Cash and cash equivalents were $32.9 million at March 31, 2023, compared with $49.3 million a year earlier. Working capital was $75.6 million versus $76.3 million. Inventory increased to $34.6 million from $24.6 million, primarily as the company purchased additional inventory to mitigate supply-chain risks.
Debt consisted of $172.5 million principal amount of 1.375% convertible senior notes due August 2025, carried at $170.3 million, and $13.0 million outstanding under the revolving credit facility. Mesa repaid $36.0 million under the credit facility during fiscal 2023 and an additional $3.0 million in April 2023. The company was in compliance with its debt covenants at March 31, 2023.
Mesa paid quarterly dividends of $0.16 per share, or $0.64 per share for fiscal 2023, and stated that it expected to continue dividends at a level consistent with historical practice.
Segment performance
| Segment | FY2023 revenue | Year-over-year change | FY2023 gross margin |
|---|---|---|---|
| Clinical Genomics | $62.3 million | 90% | 52% |
| Sterilization and Disinfection Control | $64.6 million | 9% | 72% |
| Biopharmaceutical Development | $47.4 million | 4% | 64% |
| Calibration Solutions | $44.8 million | Down 4% | 54% |
- Clinical Genomics: Results benefited from a full-year contribution from Agena, compared with only part of fiscal 2022. Organic performance was adversely affected by foreign exchange, COVID-19 restrictions in China, and the expected loss of Sema4 business.
- Sterilization and Disinfection Control: Revenue benefited from higher manufacturing capacity, price increases, and product mix. Margin declined due to labor, temporary staffing, freight, and currency costs.
- Biopharmaceutical Development: Revenue increased through product adoption and pricing, partially offset by foreign exchange. Gross margin improved modestly.
- Calibration Solutions: Revenue declined because raw-material shortages constrained production and extended customer lead times. Production conditions improved somewhat in the fourth quarter.
Material changes versus the prior comparable period
- Revenue increased 19%, largely due to the Agena acquisition, but organic growth was only 0.6%.
- Operating income and net income declined despite higher revenue and gross profit because operating expenses increased 25%, reflecting the expanded Agena operations and higher selling, administrative, and research and development costs.
- Nonoperating expense rose to $3.7 million from $1.1 million, primarily because of higher interest expense on the credit facility.
- Cash from operations declined as inventory purchases increased and accrued liabilities, including bonuses, decreased.
- Backlog fell to approximately $38.1 million from $56.0 million. Approximately $9 million of the prior-year backlog related to Sema4.
- Foreign currency translation reduced accumulated other comprehensive income by $16.5 million during fiscal 2023.
- Goodwill and other intangible assets totaled $503.3 million at March 31, 2023, including $135.8 million of Clinical Genomics goodwill and $140.7 million of Clinical Genomics intangible assets subject to potential future impairment.
Guidance, outlook, risks, contingencies, and unusual items
Management did not provide formal consolidated revenue or earnings guidance in the supplied filing. Management indicated that the ongoing effective tax rate would generally be approximately 26%, subject to share-based compensation tax effects and acquisition accounting.
- Sema4 is exiting reproductive-health screening and expects to significantly reduce future orders. Sema4 generated approximately $4.6 million of fiscal 2023 revenue and $8.2 million during the first twelve months of Mesa’s ownership of Agena. Mesa implemented a Clinical Genomics reduction-in-force and expects more than $4.0 million in annualized savings.
- Clinical Genomics goodwill and intangible assets were not impaired at March 31, 2023, but management stated that impairment in the near term is reasonably possible if performance, customer mix, market conditions, or forecasts deteriorate.
- Mesa identified two material weaknesses in internal control over financial reporting: inadequate management review of fair-value calculations, including the preliminary Belyntic valuation, and inadequate review controls for identifying goodwill-impairment triggers. The independent auditor issued an adverse opinion on internal control effectiveness.
- The Belyntic acquisition valuation remained preliminary and subject to revision. Up to $1.5 million of contingent consideration was recorded at a fair value of $1.19 million, contingent on patent approvals.
- Key operating risks include supply-chain constraints, inflation, labor availability, foreign currency volatility, customer capital-spending trends, competition, regulatory compliance, cybersecurity, data privacy, and geopolitical and trade risks.
- The $172.5 million convertible notes mature in August 2025. Mesa may need to refinance, use cash, issue shares, or use a combination of cash and shares to settle the notes.
- The company had no material legal proceedings identified by management as of March 31, 2023. The filing text does not provide formal forward-looking financial targets beyond the tax-rate commentary and stated operating expectations.
Important facts for investors to verify
- Confirm the requested period: the supplied filing is for fiscal year ended March 31, 2023, not 2021 Q4.
- Reconcile reported revenue growth with organic growth of only 0.6% and assess the sustainability of post-Agena results.
- Monitor Sema4-related revenue attrition, Clinical Genomics cost reductions, and new Chinese IVD-panel approvals.
- Evaluate liquidity and refinancing plans for the 2025 convertible notes relative to cash, operating cash flow, credit-facility availability, and potential equity issuance.
- Track remediation of the two material weaknesses and any resulting restatement, valuation adjustment, or reporting delay.
- Assess impairment sensitivity for the substantial goodwill and intangible-asset balances, particularly Clinical Genomics.
- Review inventory growth, supply-chain recovery, backlog trends, foreign-exchange effects, and margin effects from labor and freight inflation.
- Verify the continuation of quarterly dividends in light of reduced earnings, debt maturities, acquisition plans, and capital requirements.